Anti-HIV-1 humoral immune response in Brazilian patients

Brun-Vezinet, 1984, Prevalence of antibodies to lymphadenopathy-associated retrovirus in African patients with AIDS, Science, 226, 453, 10.1126/science.6238406 Schupbach, 1984, Antigens on HTLV-infected cells recognized by leukemia and AIDS sera are related to HTLV viral glycoprotein, Science, 224, 607, 10.1126/science.6324349 Weiss, 1985, Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications, JAMA, 253, 221, 10.1001/jama.1985.03350260073029 Sandstrom, 1985, Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells, Transfusion, 25, 308, 10.1046/j.1537-2995.1985.25485273806.x Sarngadharan, 1985, Immunological properties of the gag protein p24 of the acquired immunodeficiency syndrome retrovirus (human T-cell leukemia virus type III), Proc Natl Acad Sci USA, 82, 3481, 10.1073/pnas.82.10.3481 Diário Oficial da União, Portaria 721, 09 de agosto de 1989. Ho, 1985, Antibody to lymphoadenopathy-associated virus, N Engl J Med, 312, 649, 10.1056/NEJM198503073121015 Robert-Guroff, 1985, HTLV-III neutralising antibodies in patients with AIDS and AIDS-related complex, Nature (London), 316, 72, 10.1038/316072a0 Weiss, 1985, Neutralisation of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients, Nature (London), 316, 69, 10.1038/316069a0 Matthews, 1994, Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development, AIDS Res Hum Retroviruses, 10, 631, 10.1089/aid.1994.10.631 Parren, 1997, Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design, Immunol Lett, 57, 105, 10.1016/S0165-2478(97)00043-6 Jackson, 1988, Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS, Lancet, 2, 647, 10.1016/S0140-6736(88)90468-0 Karpas, 1988, Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome, Proc Natl Acad Sci USA, 85, 9234, 10.1073/pnas.85.23.9234 Prince, 1991, Prevention of HIV infection by passive immunization with HIV immunoglobulin, AIDS Res Hum Retroviruses, 7, 971, 10.1089/aid.1991.7.971 Karwowska, 1991, Passive immunization for the treatment and prevention of HIV infection, Biotechnol Ther, 2, 31 Stiehm, 2000, Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273), J Infect Dis, 181, 548, 10.1086/315224 Veljkovic, 2001, The role of passive immunization in hiv-positive patients: a case report, Chest, 120, 662, 10.1378/chest.120.2.662 Baba, 2000, Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection, Nat Med, 6, 200, 10.1038/72309 Mascola, 2000, Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies, Nat Med, 6, 207, 10.1038/72318 Hofmann-Lehmann, 2001, Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission?, J Med Primatol, 30, 190, 10.1034/j.1600-0684.2001.d01-52.x Parren, 2001, Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro, J Virol, 75, 8340, 10.1128/JVI.75.17.8340-8347.2001 Ruprecht, 2001, Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies, Transfus Clin Biol, 8, 350, 10.1016/S1246-7820(01)00187-2 Nishimura, 2002, Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies, J Virol, 76, 2123, 10.1128/jvi.76.5.2123-2130.2002 Ferrantelli, 2002, Neutralizing antibodies against HIV—back in the major leagues?, Curr Opin Immunol, 14, 495, 10.1016/S0952-7915(02)00362-X Xu, 2002, Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against, HIV Vaccine, 20, 1956, 10.1016/S0264-410X(02)00077-4 Mascola, 2002, Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1, Vaccine, 20, 1922, 10.1016/S0264-410X(02)00068-3 Xiao, 2002, Neutralizing antibodies mechanism of neutralization and protective activity against HIV-1, Immunol Res, 25, 193, 10.1385/IR:25:3:193 Dianzani, 2002, Is human immunodeficiency virus RNA load composed of neutralized immune complexes?, J Infect Dis, 185, 1051, 10.1086/340043 Koup, 1994, Temporal association of cellular immune responses with the initial control of viremia in primary immunodeficiency virus type 1 syndrome, J Virol, 68, 4650, 10.1128/JVI.68.7.4650-4655.1994 Borrow, 1995, Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression, J Virol, 69, 1059, 10.1128/JVI.69.2.1059-1070.1995 Osmanov, 2002, Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000, J Acquir Immune Defic Syndr, 29, 184, 10.1097/00042560-200202010-00013 Buchbinder, 1994, Long-term HIV-1 infection without immunologic progression, AIDS, 8, 1123, 10.1097/00002030-199408000-00014 Kostrikis, 1996, J Virol, 70, 445, 10.1128/JVI.70.1.445-458.1996 Moore, 1996, Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes, J Virol, 70, 427, 10.1128/JVI.70.1.427-444.1996 Nyambi, 1996, Multivariate analysis of human immunodeficiency virus type 1 neutralization data, J Virol, 70, 6235, 10.1128/JVI.70.9.6235-6243.1996 Pau, 1993, Highly specific V3 peptide enzyme immunoassay for serotyping HIV-1 specimens from Thailand, AIDS, 7, 337, 10.1097/00002030-199303000-00005 Weber, 1996, Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization, J Virol, 70, 7827, 10.1128/JVI.70.11.7827-7832.1996 Garcia-Albert, 2001, HIV type 1 non-B subtype prevalence in Spain, 1997–1998, AIDS Res Hum Retroviruses, 17, 1317, 10.1089/08892220152596560 Morgado, 2002, HIV-1 polymorphism: a challenge for vaccine development—a review, Mem Inst Oswaldo Cruz, 97, 143, 10.1590/S0074-02762002000200001 Sabino, 1994, Identification of human immunodeficiency virus type 1 envelope genes recombinant between subtypes B and F in two epidemiologically linked individuals from Brazil, J Virol, 68, 6340, 10.1128/JVI.68.10.6340-6346.1994 Carrow, 1991, High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas, AIDS Res Hum Retroviruses, 7, 831, 10.1089/aid.1991.7.831 Bongertz, 1994, Analysis of antibody specificity against the third variable region of the envelope gp120 of HIV-1 in plasma from HIV-1 positive individuals resident in Brazil, Braz J Med Biol Res, 27, 1225 Cheingsong-Popov, 1994, Serotyping HIV type 1 by antibody binding to the V3 loop: relationship to viral genotype. WHO Network for HIV Isolation and Characterization, AIDS Res Hum Retroviruses, 10, 1379, 10.1089/aid.1994.10.1379 Couto-Fernandez, 1994, Genetic and antigenic variability of HIV type 1 in Brazil, AIDS Res Hum Retroviruses, 10, 1157, 10.1089/aid.1994.10.1157 Pau, 1994, Antigenic variation and serotyping of HIV type 1 from four World Health Organization-sponsored HIV vaccine sites. WHO Network for HIV Isolation and Characterization, AIDS Res Hum Retroviruses, 10, 1369, 10.1089/aid.1994.10.1369 Peeters, 1994, Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions, AIDS, 8, 1657, 10.1097/00002030-199412000-00003 Bongertz, 1998, Neutralization susceptibility of B subtype variant B primary HIV-1 isolates, Scand J Immunol, 47, 603, 10.1046/j.1365-3083.1998.00345.x Pinto, 1995, V3 peptide binding pattern and HIV-1 transmission route in Rio de Janeiro, Mem Inst Oswaldo Cruz, 90, 683, 10.1590/S0074-02761995000600004 Van den Haesevelde, 1998, Effect on serological reactivity of P to W substitution in the apex of the V3 loop of the HIV-1 subtype B glycoprotein, J AIDS, 17, 91 Caterino-de-Araujo, 1999, Use of V3 loop peptide-specific antibody evaluation for subtyping HIV-1: results of a vertical transmission study from Sao Paulo, Brazil, J Trop Pediatr, 45, 265, 10.1093/tropej/45.5.265 Casseb, 2002, Serotyping HIV-1 with V3 peptides: detection of high avidity antibodies presenting clade-specific reactivity, Braz J Med Biol Res, 35, 369, 10.1590/S0100-879X2002000300013 Guimarães, 2002, High frequency of recombinant genomes in HIV-1 samples from Brazilian southeastern and southern regions, AIDS Res Hum Retrov, 18, 1261, 10.1089/088922202320886307 Bongertz, 1994, Correlation between anti-V3 peptide and neutralizing antibodies in plasma from HIV-1 infected individuals resident in Brazil, Mem IOC, 89, 113 Cheingsong-Popov, 1998, Serotyping of HIV type 1 infections: definition, relationship to viral genetic subtypes, and assay evaluation. UNAIDS Network for HIV-1 Isolation and Characterization, AIDS Res Hum Retroviruses, 14, 311, 10.1089/aid.1998.14.311 Devito, 1998, Seroreactivity to HIV-1 V3 subtypes A to H peptides of Argentinian HIV-positive sera, J Acquir Immune Defic Syndr Hum Retrovirol, 17, 156, 10.1097/00042560-199802010-00009 Bongertz, 1999, Anti-HIV-1 seroreactivity in distinct transmission risk groups, J Clin Virol, 12, 37, 10.1016/S0928-0197(98)00068-3 Bongertz V, Ouverney EP, Teixeira SLM, Silva-de-Jesus C, Hacker MA, Morgado MG, et al. Higher anti-HIV-1 antibody titers in injection drug users compared to sexually infected individuals. Submitted for publication, 2002. Teixeira, 2001, Low seroprevalence of HIV-1 infection and detection of B-F HIV-1 subtypes by gag/env-HMA among injection drug users (IDUs) of Rio de Janeiro, Brazil, Braz J Inf Dis, 5, S10 Guimarães, 2002, Polymorphism of the Human Immunodeficiency Virus Type 1 in Brazil: Genetic characterization of the nef gene and implications for vaccine design, Mem Inst Oswaldo Cruz, 10.1590/S0074-02762002000400013 Caride, 2000, Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART, Virology, 275, 107, 10.1006/viro.2000.0487 Barin, 1996, Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: an approach for HIV type 1 serological subtyping, AIDS Res Hum Retroviruses, 12, 1279, 10.1089/aid.1996.12.1279 Guevara, 2002, Maternal HIV-1 antibody and vertical transmission in subtype C virus infection, J Acquir Immune Defic Syndr, 29, 435, 10.1097/00126334-200204150-00002 Bongertz, 2001, Vertical HIV-1 transmission: importance of neutralizing antibody titer and specificity, Scand J Immunol, 53, 1, 10.1046/j.1365-3083.2001.00866.x Moore, 1995, A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B, J Virol, 69, 122, 10.1128/JVI.69.1.122-130.1995 Plantier, 1998, Extent of antigenic diversity in the V3 region of the surface glycoprotein, gp120, of human immunodeficiency virus type 1 group M and consequences for serotyping, J Virol, 72, 677, 10.1128/JVI.72.1.677-683.1998 Bongertz, 2001, Resposta Imune Humoral à Infecção por HIV-1, Braz J Inf Dis, 5, S1 Pehrson, 1997, Longer survival after HIV infectionfor injecting drug users than for homosexual men: implications for immunology, AIDS, 11, 1007, 10.1097/00002030-199708000-00009 Ouverney EP. Anti HIV-1 humoral immune response in injecting drug users resident in Rio de Janeiro, Brazil. Molecular and Cellular Biology Post-Graduation IOC FIOCRUZ 2002 (manuscript in preparation). Prins, 1997, Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users, AIDS, 11, 1747, 10.1097/00002030-199714000-00012 Hendricks, 1998, The incubation period to AIDS in injecting drug users estimated from prevalence cohort data accounting for death prior to an AIDS diagnosis, AIDS, 12, 1537, 10.1097/00002030-199812000-00017 Sabino, 1996, Distribution of HIV-1 subtypes seen in an AIDS clinic in Sao Paulo City, Brazil, AIDS, 10, 1579, 10.1097/00002030-199611000-00018 Rossini, 2001, HIV-1 subtypes among intra-venous drug users from two neighboring cities in Sao Paulo State, Brazil, Braz J Med Biol Res, 34, 45, 10.1590/S0100-879X2001000100005 Couto-Fernandez, 1999, HIV-1 subtyping in Salvador, Bahia, Brazil: a city with African sociodemographic characteristics, J Acquir Immune Defic Syndr, 22, 288, 10.1097/00042560-199911010-00011 Vicente, 2000, The HIV epidemic in the Amazon Basin is driven by prototypic and recombinant HIV-1 subtypes B and F, J Acquir Immune Defic Syndr, 23, 327, 10.1097/00042560-200004010-00008 Tanuri, 1999, HIV-1 subtypes among blood donors from Rio de Janeiro, Brazil, J Acquir Immune Defic Syndr Hum Retrovirol, 20, 60, 10.1097/00042560-199901010-00009 Bures, 2002, Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa, J Virol, 76, 2233, 10.1128/jvi.76.5.2233-2244.2002 Hendry, 1996, Immunoreactivity of Brazilian HIV isolates with different V3 motifs, Mem Inst Oswaldo Cruz, 91, 347 Machado, 1995, Neutralizing antibodies against highly cytopathic Zairian human immunodeficiency type-1 virus (HIV-1) NDK are present in sera outside Africa, Vaccine, 13, 321, 10.1016/0264-410X(95)93321-Y Machado, 1997, Neutralizing antibodies in Brazilian sera against three strains of human immunodeficiency virus type 1 (HIV-1), Rev Inst Med Trop Sao Paulo, 39, 319, 10.1590/S0036-46651997000600002 Bongertz, 1997, Correlation between susceptibility of primary HIV-1 isolates to autologous and heterologous neutralizing antibodies, AIDS, 11, 977, 10.1097/00002030-199708000-00004 Scarlatti, 1993, Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates, J Infect Dis, 168, 207, 10.1093/infdis/168.1.207 Louisirirotchanakul, 1999, Role of maternal humoral immunity in vertical transmission of HIV-1 subtype E in Thailand, J Acquir Immune Defic Syndr, 21, 259, 10.1097/00126334-199908010-00001 Lathey, 1999, Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission, J Infect Dis, 180, 344, 10.1086/314886 Burton, 1994, Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody, Science, 266, 1024, 10.1126/science.7973652 Trkola, 1996, Human monoclonal antibody 2G12 defines a distinct neutralization epitope on the gp120 glycoprotein of HIV-1, J Virol, 70, 1100, 10.1128/JVI.70.2.1100-1108.1996 Conley, 1994, Neutralization of divergent HIV-1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody, Proc Natl Acad Sci USA, 91, 3348, 10.1073/pnas.91.8.3348 Posner, 1991, An IgG human monoclonal antibody that reacts with HIV-1/gp120, inhibits virus binding to cells and neutralizes infection, J Immunol, 146, 4325, 10.4049/jimmunol.146.12.4325 Moore, 1999, HIV-1 neutralizing antibodies: how full is the bottle?, Nat Med, 5, 142, 10.1038/5502